REGENXBIO INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.15 USD | +2.22% |
|
-2.88% | -9.81% |
| 05:39pm | HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating | MT |
| 09/05 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
15.8
USD
Average target price
39.08
USD
Spread / Average Target
+147.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.81% | 778M | |
| +7.83% | 111B | |
| +11.27% | 106B | |
| -12.26% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.92% | 16.81B | |
| +38.47% | 12.54B | |
| -24.52% | 8.09B |
- Stock Market
- Equities
- RGNX Stock
- News REGENXBIO Inc.
- RBC Lowers REGENXBIO's PT to $25 From $29, Keeps Sector Perform, Speculative Risk Rating